NEW YORK (GenomeWeb) – Enzo Biochem reported after the close of the market on Monday that its second quarter revenues rose 3 percent year over year, thanks almost entirely to a 4 percent increase in it clinical laboratory service revenues.

For the three months ended Jan. 31, the firm reported total revenues of $27.0 million, up from $26.3 million in Q2 2017.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.